This site is intended for healthcare professionals
News

Sanofi provides update on venglustat clinical program.

Read time: 1 mins
Last updated:4th Jun 2021
Published:4th Jun 2021
A pivotal Phase II/III study of GZ/SAR 402671 (venglustat) in autosomal dominant polycystic kidney disease (ADPKD) did not meet futility criteria, and the company has halted the clinical program in ADPKD.
Condition: Polycystic Kidney Disease
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest